JADE101 IgA Nephropathy Phase 2 Study

NIH registered a new Phase 2 clinical trial for JADE101, an investigational drug for immunoglobulin A nephropathy, on ClinicalTrials.gov. The study is described as open-label and will characterize both safety and efficacy in the target patient population. Pharmaceutical companies and clinical investigators involved in kidney disease drug development may monitor this trial as an indicator of emerging therapies in the IgA nephropathy space.